智翔金泰跌2.28% 连亏5年2023年上市募资34.7亿元

Core Viewpoint - The stock price of Zhixiang Jintai (688443.SH) has declined, closing at 27.80 yuan, with a drop of 2.28%, currently in a state of breaking issue [1] Group 1: Financial Performance Forecast - For the year 2025, Zhixiang Jintai expects to achieve an operating revenue between 209.45 million yuan and 250.88 million yuan, an increase of 179.35 million yuan to 220.78 million yuan compared to the previous year, representing a year-on-year growth of 595.96% to 733.62% [1] - The company anticipates a net loss attributable to shareholders of the parent company between 480.64 million yuan and 587.45 million yuan for 2025, which is a reduction in loss by 209.83 million yuan to 316.64 million yuan compared to the previous year, a year-on-year decrease of 26.32% to 39.71% [1] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to be between 523.63 million yuan and 630.44 million yuan, with a reduction in loss by 173.89 million yuan to 280.70 million yuan compared to the previous year, a year-on-year decrease of 21.62% to 34.90% [1] Group 2: Historical Financial Data - From 2021 to 2024, the net profit attributable to shareholders of the listed company was -322 million yuan, -576 million yuan, -801 million yuan, and -797 million yuan respectively [2] - The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was -334 million yuan, -645 million yuan, -813 million yuan, and -804 million yuan respectively during the same period [2] Group 3: IPO and Fundraising - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with a public offering of 91.68 million shares at a price of 37.88 yuan per share [2] - The total amount raised from the initial public offering was 3.47 billion yuan, with a net amount of 3.29 billion yuan after deducting issuance costs, which was 688.60 million yuan less than the originally planned fundraising amount [2] - The company intended to raise 3.98 billion yuan for the expansion of the antibody industrialization base project, the second phase of the antibody industrialization base project, antibody drug research and development, and to supplement working capital [2]